Transcept Pharmaceuticals, Inc. (Nasdaq:TSPT) announced its plan to resubmit to the U.S. Food and Drug Administration (FDA) its New Drug Application (NDA) seeking approval of Intermezzo® (zolpidem tartrate sublingual tablet) for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
Read full article:http://bestotc.com/18217/stock-alerts/tspt-clno-trid-blti-stock-updates-by-bestotccom/
(TSPT, CLNO, TRID, BLTI) Stock Updates by BestOtc.com
September 16th, 2011 at 09:02 am